Media stories about ConforMIS (NASDAQ:CFMS) have been trending somewhat positive on Tuesday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ConforMIS earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned press coverage about the medical instruments supplier an impact score of 47.7453175408435 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Hot Stock’s Alert – ConforMIS Inc (NASDAQ: CFMS) – Stocks Pen (stockspen.com)
- Active Mover – ConforMIS Inc (NASDAQ: CFMS) – Alpha Beta Stock (alphabetastock.com)
- Investors Feeling Jittery About ConforMIS, Inc. (CFMS), Chipotle … – ExpressNewsline (expressnewsline.com)
- ConforMIS (CFMS) Coverage Initiated by Analysts at Cowen (americanbankingnews.com)
ConforMIS (NASDAQ CFMS) traded down $0.01 during trading on Tuesday, hitting $1.41. 324,700 shares of the stock traded hands, compared to its average volume of 778,104. The company has a market capitalization of $81.82 and a PE ratio of -1.14. The company has a debt-to-equity ratio of 0.52, a quick ratio of 5.38 and a current ratio of 6.19. ConforMIS has a 52-week low of $1.15 and a 52-week high of $5.98.
CFMS has been the topic of several analyst reports. Zacks Investment Research downgraded shares of ConforMIS from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. BTIG Research reaffirmed a “hold” rating on shares of ConforMIS in a report on Thursday, November 2nd. JPMorgan Chase & Co. downgraded shares of ConforMIS from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 2nd. Oppenheimer set a $4.00 price target on shares of ConforMIS and gave the company a “buy” rating in a report on Thursday, February 8th. Finally, Canaccord Genuity reduced their price objective on shares of ConforMIS from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Thursday, February 8th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $4.75.
In other news, CEO Mark A. Augusti sold 16,548 shares of ConforMIS stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $2.27, for a total transaction of $37,563.96. Following the sale, the chief executive officer now owns 285,007 shares in the company, valued at $646,965.89. The transaction was disclosed in a document filed with the SEC, which is available at this link. In the last quarter, insiders have sold 43,691 shares of company stock worth $91,154. Company insiders own 9.55% of the company’s stock.
ConforMIS Company Profile
ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.